Disease Landscape and Forecast Insights

Gauging Physicians’ and Payers’ Evolving Receptivity to Emerging Symptomatic vs. Disease-Modifying Therapies With aging populations, the seven major pharmaceutical markets face an ever-…

LaunchTrends: Gilotrif is a series of three post-launch syndicated reports designed to track physician perception and uptake of newly launched Gilotrif (Boehringer Ingelheim’s afatinib)…

Based on a survey of 100 medical oncologists and 30 MCO pharmacy and medical directors, this report explores the market access challenges facing key current and emerging brands used in the…

Payer and Physician Receptivity to Novel Treatments—Which Emerging Drugs Excite Them? Hyperphosphatemia, or treatment of elevated serum phosphorous levels, typically found as a complication of…

Payer and Physician Receptivity to Novel Treatments—Which Emerging Drugs Excite Them? Hyperphosphatemia, or treatment of elevated serum phosphorous levels, typically found as a complication of…

Amid significant unmet need, what attributes do gastroenterologists and payers expect of a therapy with a mechanism of action different from that of the currently available TNF-alpha inhibitors…

As Healthcare Providers Seek to Contain Growing Costs, New Agents Will Need to Demonstrate Improvements Across Efficacy, Safety, and Delivery Attributes to Justify Premium Pricing The increasing…

Amid significant unmet need, what attributes do gastroenterologists and payers expect of a therapy with a mechanism of action different from that of the currently available TNF-alpha inhibitors…

As Healthcare Providers Seek to Contain Growing Costs, New Agents Will Need to Demonstrate Improvements Across Efficacy, Safety, and Delivery Attributes to Justify Premium Pricing The increasing…

Treatment Choices Are Limited, but Oncologists’ Receptivity to Targeted Agents Presents a Lucrative Opportunity The introduction of the HER2-targeting agent trastuzumab (Roche/Genentech/Chugai…

Treatment Choices Are Limited, but Oncologists’ Receptivity to Targeted Agents Presents a Lucrative Opportunity The introduction of the HER2-targeting agent trastuzumab (Roche/Genentech/Chugai…

In the Era of Generic Cardiovascular Agents, Can Emerging Therapies Achieve Substantial Clinical Differentiation to Gain Widespread Use? Chronic heart failure (CHF) describes the long-term…